Work

Effect of ambrisentan in patients with systemic sclerosis and mild pulmonary arterial hypertension: Long-term follow-up data from EDITA study

Year: 2024

Type: conference-paper

Abstract: Introduction: In the EDITA trial, patients with systemic sclerosis (SSc) and mild pulmonary vascular disease (PVD) treated with ambrisentan had a significant decline of pulmonary vascular resistance (PVR) but not of mean pulmonary arterial pressure (mPAP) vs. placebo after six months [ref:1]. [for full text, please go to the a.m. URL]

Source: German Medical Science (German Research Foundation)

DOI: 10.3205/24dgrh227

Authors: Xanthouli, Panagiota, Uesbeck, Paul, Lorenz, Hanns-Martin, Blank, Norbert, Eichstaedt, Christina, Harutyunova, Satenik, Egenlauf, Benjamin, Coghlan, Gerry, Denton, Christopher P., Grünig, Ekkehard, Benjamin, Nicola

Institutions: Heidelberg University, University Hospital Heidelberg, The Royal Free Hospital

Language: English

Topic: Pulmonary Hypertension Research and Treatments

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

OpenAlex ID: W6908573870

FWCI:

Cites:

Cited by:

Related to: